Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
International multicentre phase 2 trial of booster mRNA vaccination against SARS-CoV-2 in previously vaccinated adults
2021-004889-35Phase 2Completed
- Sponsor
- University College Dublin
- Start
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of raxtozinameran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University College Dublin. Primary endpoints: Composite humoral immune response endpoint and Cellular immune response change. Started Sep 2021; status: completed.
02
Drugs
raxtozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-004889-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004889-35.